4793: Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral Purine Nucleotide Prodrug for COVID-19 Infection
March 29, 2022 at 04:28 pm EDT
Share
Introduction
AT-527 (bemnifosbuvir), the hemisulfate salt of AT-511 (free base), is an orally administered double prodrug of a guanosine nucleotide analog that is converted after multi-step activation to the active 5-triphosphate (TP) metabolite (AT-9010). AT-9010 inhibits the replication of COVID-19 viruses through a dual mechanism of action targeting both NiRAN and RdRp domains (Shannon et al. 2022). It has demonstrated potent anti-COVID-19 activity in vitro (EC90=0.5 µM) and exhibited a well-tolerated safety profile in patients. Here we report the potential effects of AT-527 on the reproductive and developmental function. The general nonclinical toxicity profile of AT-527 is presented in P#858.
Materials and Methods
AT-527 was supplied by Atea Pharmaceuticals, Inc. and formulated in PEG-400 (40%, v/v) / Solutol HS15 (10%, v/v)/ 100 mM Citrate buffer pH 4.5±0.2 (50%, v/v). The dose levels were expressed as free base (AT-511)-equivalent.
Crl:CD(SD) Sprague Dawley rats were obtained from Charles River Laboratories, Raleigh, NC. Female New Zealand White [Crl:KBL(NZW)] rabbits were obtained from Charles River Laboratories, Saint Constant, Quebec, Canada. All animal studies were conducted in a facility fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals and Animal Welfare and approved by the local Institutional Animal Care and Use Committee (IACUC). All definitive studies were conducted in compliance with GLP regulations.
One-way analysis of variance (ANOVA) and pairwise comparisons (Dunnett's test) were performed. Statistical significance was reported at the probability levels of 0.05 and 0.01.
Results
A standard DART program was conducted to characterize the potential effects of AT-527 on the developmental and reproductive functions as shown in Table 1.
.
Table 1: Reproductive and Developmental Toxicity Studies with AT-527 in Rats and Rabbits
Study Type
Summary of Results
Seg I, Fertility and early embryo-fetal development study in rats
• 0, 250, 500 and 1000 mkd; 22/sex/group
• ↑incidence of abnormal breathing sounds at 500 and 1000 mkd
• ↓body weights (ca 4% to 13% Days 36 to 58) and body weight gains (ca 10% Days 1 to 57) in males at 1000 mkd
• NOAEL: 1000 mkd
Seg II, DRF Embryo-fetal development study in rats
• 0, 250, 500 and 1000 mkd, GD 7 to 17, Tox: 6 ♀/group; TK: 9 ♀/group for dosed groups
• No findings at doses up to 1000 mkd
Seg II, Definitive Embryo-fetal development study in rats
• 0, 250, 500 and 1000 mkd, GD 7 to 17, Tox: 22 ♀/group; TK: 9 ♀/group except for 3 females for control
• NOAEL: 1000 mkd for maternal and developmental toxicities
Seg II, DRF Embryo-fetal development study in rabbits
• 0, 125, 250, 500 mkd, GD 7 to 19, 6 ♀/group
• At 125 mkd: apparent reductions of FC, minimal maternal BW loss, slightly lower fetal body weight
• ≥ 250 mkd: mortalities with markedly ↓FC, BW loss and clinical observations
Seg II, Definitive Embryo-fetal development study in rabbits
• 0, 25, 50, 100 mkd, dosing on GD 7 to 19, 22 ♀/group
• ≥ 25 mkd: ↓maternal FC and BW gain
• At 100 mkd: abortions and mortality (Table 2) with ↓FC (Table 3) and BW loss during dosing period (GD7-19) (Figure 1)
• NOAEL: 100 mkd for developmental toxicity
Seg III, Pre- and postnatal development study in rats with behavioral/function al evaluation
• 0, 250, 500 and 1000 mkd, dosing on GD 7 to LD 20, 22 ♀/group
• NOAEL: 1000 mkd for maternal and developmental toxicities
Table 2: Summary of Mortality and Abortions in the Definitive Seg II Study in Rabbits
Mode of Death
Dose (mkd)
Vehicle
25
50
100
Abortion
NA
1/22
1/22
3/22
Unscheduled Sacrifice
NA
NA
NA
1/22
Total
0/22
1/22
1/22
4/22
mkd = mg/kg/day, NA = not applicable
Table 3: Summary of Food Consumption (g/day) in the Definitive Seg II Study in Rabbits
Interval
Dose (mkd)
Vehicle
25
50
100
GD7-20
M ± SD
102 ± 36
89 ± 39
85 ± 34
71 ± 31
Change
NA
↓13%
↓17%
↓37%
GD20-29
M ± SD
115 ± 30
111 ± 29
118 ± 32
128 ± 29
Change
NA
↓3%
↑3%
↑11%
GD7-29
M ± SD
108 ± 27
98 ± 26
100 ± 28
97 ± 29
Change
NA
↓9%
↓8%
↓10%
mkd = mg/kg/day, GD = gestation day, M = mean, SD = standard deviation, NA = not applicable
Figure 1: Summary of Mean Body Weight in the Definitive Seg II Study in Rabbits
Mean body weight (g)
4150
4100
4050
4000
3950
3900
3850
3800
3750
4
8
12
16
20
24
Days relative to mating0 mg/kg/d25 mg/kg/d50 mg/kg/d
28
32
100 mg/kg/d
Conclusions
➢There were no AT-527-related effects on the fertility, reproduction, embryofetal and postnatal development in rats. The NOAEL was 1000 mg/kg/day, the top dose tested, in Segment I, II and III studies.
➢In rabbits, there were no AT-527-related embryofetal abnormalities at doses up to 100 mg/kg/day even in the presence of evident maternal toxicities at 100 mg/kg/day, i.e., body weight loss, abortions, and mortalities, which were secondary to reduced food consumption.
➢The maternal toxicity of AT-527 in rabbits was confounded by the toxicity caused by the vehicle as the PEG-400-containing complex vehicle itself resulted in reduced food consumption and body weight loss noted in a 7-day tolerability study in nonpregnant female rabbits.
References
1.Shannon A, Fattorini V, SamaB, et al.. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nature Communications 2022, 13:621.
Acknowledgments
Disclosures: SL, SG, AM and JPS are employees of Atea Pharmaceuticals, Inc.
We thank the staff of Charles River Laboratories for the excellent work they have accomplished.
We also thank Kerry-Ann da Costa for her excellent assistance in preparing this poster.
www.postersession.com
Attachments
Original Link
Original Document
Permalink
Disclaimer
Atea Pharmaceuticals Inc. published this content on 28 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 March 2022 20:27:06 UTC.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.